Skip to main content
SpringerLink
Log in

Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Methotrexate is the most common disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis (RA). Current evidence supports its efficacy in the treatment of RA, resulting in improved short-term disease control and long-term outcomes in terms of radiographic progression. Oral methotrexate has traditionally been used first-line due to various reasons, including ease of administration, low cost and easy availability. A methotrexate dose of >15 mg/week is generally required for disease control but oral methotrexate may be only partially effective or poorly tolerated in some patients. The rationale for using subcutaneous (SC) methotrexate is based on its improved bioavailability at higher doses and better tolerability in some patients who have side effects when receiving oral methotrexate. Current guidance advocates ‘treating to target’, with the aim of inducing remission in RA patients. In some patients, this can be achieved using methotrexate alone or in combination with other traditional DMARDs. Patients who have not responded to two DMARDs, including methotrexate, are eligible for biological therapy as per current National Institute for Health and Care Excellence (NICE) guidance in the UK. Biological treatments are expensive and using SC methotrexate can improve disease control in RA patients, thus potentially avoiding or delaying the requirement for future biological treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford). 2002;41:793–800.

    Article  CAS  PubMed  Google Scholar 

  2. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2015-207524 (Epub 12 May 2015).

    Google Scholar 

  3. Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74(1):27–34.

    Article  CAS  PubMed  Google Scholar 

  4. Dougados M, Cpombe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. National Institute for Health and Care Excellence. NICE Guidance CG79. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. Available at: https://www.nice.org.uk/guidance/cg79. Accessed 15 Aug 2015.

  6. Ward JR. Historical perspective on the use of methotrexate for the treatment of rheumatoid arthritis. J Rheumatol Suppl. 1985;12(Suppl 12):3–6.

    PubMed  Google Scholar 

  7. Paulus HE. FDA Arthritis Advisory Committee Meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs. DMSO in scleroderma. Arthritis Rheum. 1986;29:1289–90.

    Article  CAS  PubMed  Google Scholar 

  8. Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12–9.

    Article  CAS  PubMed  Google Scholar 

  9. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Montesinos MC, Yap JS, Desai A, et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 2000;43:656–63.

    Article  CAS  PubMed  Google Scholar 

  11. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163–72.

    Article  CAS  PubMed  Google Scholar 

  12. Herman RA, van Pedersen P, Hoffman J, et al. Pharmacokinetics of low dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989;78:165–71.

    Article  CAS  PubMed  Google Scholar 

  13. Freeman-Narrod M, Gerstley BJ, Engstrom P, et al. Comparison of serum concentrations of methotrexate after various routes of administration. Cancer. 1975;36:1619–24.

    Article  CAS  PubMed  Google Scholar 

  14. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis Ann Rheum Dis. 2004;63:1232–4.

    CAS  PubMed  Google Scholar 

  15. Bingham SJ, Buch MH, Lindsay S, et al. Parenteral methotrexate should be given before biological therapy. Rheumatology. 2003;42(8):1009–10.

    Article  CAS  PubMed  Google Scholar 

  16. Rau R, Herborn G, Menninger H, et al. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol. 1997;36(3):345–52.

    Article  CAS  PubMed  Google Scholar 

  17. Rau R, Herborn G, Karger T, et al. A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months. Semin Arthritis Rheum. 1991;21(2 Suppl 1):13–20.

    Article  CAS  PubMed  Google Scholar 

  18. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20(11):1845–9.

    CAS  PubMed  Google Scholar 

  19. Nikiphorou E, Negoescu A, Fitzpatrick JD, et al. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol. 2014;33(5):609–14.

    Article  PubMed  Google Scholar 

  20. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81.

    Article  CAS  PubMed  Google Scholar 

  21. Bakker MF, Jacobs JW, Welsing PM, et al. Utrecht Arthritis Cohort Study Group. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69(10):1849–52.

    Article  CAS  PubMed  Google Scholar 

  22. Müller RB, von Kempis J, Haile SR, et al. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum. 2015;45(1):28–34.

    Article  PubMed  Google Scholar 

  23. Hazlewood GS, Thorne JC, Pope JE, For the CATCH Investigators, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2014-206504 (Epub 15 May 2015).

    PubMed  Google Scholar 

  24. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73(8):1549–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Kromann CB, Lage-Hansen PR, Koefoed M, et al. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatolog Treat. 2015;26(2):188–90.

    Article  CAS  PubMed  Google Scholar 

  26. Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2014;66(11):1604–11.

    Article  CAS  PubMed  Google Scholar 

  27. Demary W, Schwenke H, Rockwitz K, et al. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. Patient Prefer Adherence. 2014;8:1061–71.

    PubMed Central  PubMed  Google Scholar 

  28. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis. 2009;68(7):1086–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Fitzpatrick R, Scott DGI, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32(11):1605–12.

    Article  PubMed  Google Scholar 

  30. Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol. 2014;43(6):470–6.

    Article  CAS  PubMed  Google Scholar 

  31. Nam JL, Villeneuve E, Hensor EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014;73(6):1027–36.

    Article  CAS  PubMed  Google Scholar 

  32. Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology. 2010;49(6):1197–9.

    Article  PubMed  Google Scholar 

  33. Bykerk V, Akhavan P, Hazelwood G, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough City Hospital, Bretton Gate, Peterborough, PE3 9GZ, UK

    Poonam Sharma

  2. Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK

    David G. I. Scott

Authors
  1. Poonam Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David G. I. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Poonam Sharma.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this article.

Conflicts of interest

David G. I. Scott has received funding from Medac for presenting results from the Metaject Study at EULAR 2012, as well as the Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation, and has received grant funding from Medac to support the audit of SC methotrexate in 2012/2013. Poonam Sharma has no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, P., Scott, D.G.I. Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics. Drugs 75, 1953–1956 (2015). https://doi.org/10.1007/s40265-015-0486-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0486-7

Keywords

Search

Navigation